Enhanced alveo pulmonary deposition of nebulized ciclesonide for attenuating airways inflammations: a strategy to overcome metered dose inhaler drawbacks

Autor: Amal Youssef, Shereen S. El-Husseney, Ahmed Maher, Nesrine S. El Sayed, Hanan M. El-Laithy
Rok vydání: 2021
Předmět:
aerosol
Anti-Inflammatory Agents
Pharmaceutical Science
02 engineering and technology
Ciclesonide
030226 pharmacology & pharmacy
Mice
chemistry.chemical_compound
0302 clinical medicine
Pregnenediones
nanolipid particles
Lung
Mice
Inbred BALB C
integumentary system
General Medicine
021001 nanoscience & nanotechnology
Metered-dose inhaler
Anesthesia
Corticosteroid
Female
Inflammation Mediators
0210 nano-technology
Research Article
Cell Survival
Surface Properties
medicine.drug_class
pulmonary delivery
nebulizer
RM1-950
Cell Line
Pulmonary deposition
03 medical and health sciences
Administration
Inhalation
medicine
Animals
Humans
Particle Size
Asthma
Dose-Response Relationship
Drug
business.industry
Nebulizers and Vaporizers
medicine.disease
respiratory tract diseases
Drug Liberation
Nebulizer
chemistry
Nanoparticles
bronchial asthma
ciclesonide
Therapeutics. Pharmacology
business
Zdroj: Drug Delivery, Vol 28, Iss 1, Pp 826-843 (2021)
Drug Delivery
article-version (VoR) Version of Record
DOI: 10.6084/m9.figshare.14518822.v1
Popis: Ciclesonide (CIC), an inhaled corticosteroid for bronchial asthma is currently available as metered dose inhaler (CIC–MDI) which possesses a major challenge in the management of the elderly, critically ill patients and children. In this work, nebulized CIC nano-structure lipid particles (CIC-NLPs) were prepared and evaluated for their deep pulmonary delivery and cytotoxicity to provide additional clinical benefits to patients in controlled manner and lower dose. The bio-efficacy following nebulization in ovalbumin (OVA) induced asthma Balb/c mice compared to commercial (CIC–MDI) was also assessed. The developed NLPs of 222.6 nm successfully entrapped CIC (entrapment efficiency 93.3%) and exhibited favorable aerosolization efficiency (mass median aerodynamic diameter (MMAD) 2.03 μm and fine particle fraction (FPF) of 84.51%) at lower impactor stages indicating deep lung deposition without imparting any cytotoxic effect up to a concentration of 100 μg/ml. The nebulization of 40 µg dose of the developed CIC-NLPs revealed significant therapeutic impact in the mitigation of the allergic airways inflammations when compared to 80 µg dose of the commercial CIC–MDI inhaler (Alvesco®). Superior anti-inflammatory and antioxidative stress effects characterized by significant decrease (p
Databáze: OpenAIRE
Externí odkaz: